
- Telehealth Visits
- Insurances Accepted

Rahul Aggarwal, MD
Medical Oncology (Genitourinary Cancer)- Telehealth Visits
- Insurances Accepted



Rahul Aggarwal, MD
Medical Oncology (Genitourinary Cancer)- Telehealth Visits
- Insurances Accepted
On this page
About me
Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.
As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.
Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.
Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.
Education
Board Certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Fellowship
- Hematology - Oncology, UCSF Medical Center - OMAG
Internship
- Internal Medicine, UCSF Medical Center - OMAG
School
- MD, Northwestern University Feinberg School of Medicine
Academic Title
- Professor-in-Residence
Care Keywords
Services
- Medical Oncology (Genitourinary Cancer)
Conditions
- Prostate Cancer
- Testicular Cancer
- Bladder Cancer
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Clinical trials
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Opens in a new window
Recruiting
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progressi...Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid TumorsOpens in a new window
Recruiting
Assessed by treatment-emergent adverse events (TEAEs), physical examinations (PEs), safety laboratory assessments, electrocardiograms (ECGs), and vital sign me...64Cu-GRIP B in Patients With Advanced MalignanciesOpens in a new window
Recruiting
For Cohort A, the frequency and severity of adverse events following 64Cu-GRIP B injection will be descriptively reported, using NCI Common Terminology Criteri...
Publications
Showing 1-6 of 68 reviews
- July 22, 20265 out of 5 Stars
We have recommended others
- July 22, 20265 out of 5 Stars
Dr. Agarwal is an extraordinary professional. He always makes the time to listen to my concerns and questions. I appreciate his communication style. I couldn't ask for a better physician.
- July 14, 20265 out of 5 Stars
Extremely productive initial appointment.
- July 9, 20265 out of 5 Stars
Dr Aggarwal always makes me feel I'm in very good hands.
- June 19, 20265 out of 5 Stars
Always felt l got the best of UCSF MEDICAL attention.
- June 10, 20265 out of 5 Stars
Dr Aggarwal is fantastic on all levels!!
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.